Memantine Hydrochloride Tablet
Product Images NDC 50090-6400

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-6400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine-figure1 (Memantine Figure1)

A line graph showing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment, comparing Memantine Hydrochloride and placebo groups. The y-axis represents mean change (± SEM) with clinical improvement at the top and clinical decline at the bottom. Memantine Hydrochloride is shown with a line and open circles, placebo with squares. Error bars represent SEM.*

FDA Label Image

Memantine-figure3 (Memantine Figure3)

A line graph comparing the mean change from baseline in SIB score over 28 weeks of treatment between placebo and memantine hydrochloride groups. The y-axis shows mean change with labels for clinical improvement and clinical decline, while the x-axis indicates weeks of treatment (0, 4, 12, 28). Data points for placebo (squares) show a decline over time, whereas memantine hydrochloride (circles) shows stability or slight improvement in scores.*

FDA Label Image

Memantine-figure5 (Memantine Figure5)

This line graph shows the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment for two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The y-axis represents the mean change ± SEM values, with a range from 1 to -3.5, where 0 indicates no change, positive values indicate clinical improvement, and negative values indicate clinical decline. The x-axis shows weeks of treatment from 0 to 24. Error bars represent variability around the mean for each time point.*

FDA Label Image

Memantine-figure7 (Memantine Figure7)

A line graph showing mean change from baseline in SIB Score over 24 weeks of treatment. Two lines compare Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The vertical axis ranges from -4 to 4, indicating clinical decline to clinical improvement, with error bars for SEM at each time point.*

FDA Label Image

Memantine_structure (Memantine Structure)

Chemical structure of Memantine Hydrochloride showing a cage-like adamantane backbone with an amino group (NH2) and hydrochloride (HCl) attached, and methyl groups (CH3) at specific positions.*

FDA Label Image

Label Image (Lbl500906400)

Label for Memantine Hydrochloride 10 mg tablets, a human prescription oral drug by A-S Medication Solutions. The label indicates each film-coated tablet contains 10 mg of Memantine Hydrochloride. The package contains 90 tablets with storage instructions to keep at 77 degrees Fahrenheit. The product NDC is 50090-6400-00.*

FDA Label Image

Memantine-figure2 (Memantine Figure2)

A cumulative percentage curve graph comparing placebo and memantine hydrochloride treatment groups based on ADCS-ADL change from baseline in patients. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows the cumulative percentage of patients, with memantine hydrochloride showing higher cumulative responses than placebo.*

FDA Label Image

Memantine-figure4 (Memantine Figure4)

A line graph showing the cumulative percentage of patients relative to SIB change from baseline. The graph compares two groups: placebo and Memantine hydrochloride. The x-axis represents SIB change from baseline, while the y-axis shows the cumulative percentage of patients.*

FDA Label Image

Memantine-figure6 (Memantine Figure6)

A cumulative percentage of patients graph showing the ADCS-ADL change from baseline for two treatments: Placebo/Donepezil and Memantine hydrochloride/Donepezil. The x-axis represents ADCS-ADL change from baseline, and the y-axis represents the cumulative percentage of patients. The graph compares patient response between the two treatment groups.*

FDA Label Image

Memantine-figure8 (Memantine Figure8)

A line graph showing the cumulative percentage of patients versus SIB (Severe Impairment Battery) change from baseline. Two treatment groups are compared: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, each represented by distinct lines and markers. The graph indicates changes in patient outcomes over a range of SIB score changes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.